KalVista Pharmaceuticals, Inc.
KALV · NASDAQ
9/30/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Market Cap | – | $729 | $684 | $469 |
| - Cash | $243 | $124 | $99 | $167 |
| + Debt | $148 | $6 | $6 | $6 |
| Enterprise Value | – | $611 | $591 | $308 |
| Revenue | $14 | $1 | $0 | $0 |
| % Growth | 860.2% | – | – | – |
| Gross Profit | $12 | $1 | -$16 | $0 |
| % Margin | 91% | 58.6% | – | – |
| EBITDA | -$42 | -$54 | -$55 | -$41 |
| % Margin | -308.2% | -3,798.4% | – | – |
| Net Income | -$49 | -$60 | -$52 | -$49 |
| % Margin | -361.4% | -4,214.3% | – | – |
| EPS Diluted | -0.92 | -1.12 | -1.05 | -0.92 |
| % Growth | 17.9% | -6.7% | -14.1% | – |
| Operating Cash Flow | -$33 | -$55 | -$40 | -$33 |
| Capital Expenditures | -$0 | -$0 | $0 | -$0 |
| Free Cash Flow | -$33 | -$55 | -$40 | -$33 |